Edition:
India

G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

49.11USD
20 Jun 2018
Change (% chg)

-- (--)
Prev Close
$49.11
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
98,468
52-wk High
$52.76
52-wk Low
$12.04

Chart for

About

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38... (more)

Overall

Beta: --
Market Cap(Mil.): $731.75
Shares Outstanding(Mil.): 28.29
Dividend: --
Yield (%): --

Financials

BRIEF-G1 Therapeutics Reports Qtrly Loss Per Share Of $0.70

* G1 THERAPEUTICS PROVIDES FIRST QUARTER 2018 CORPORATE AND FINANCIAL UPDATE

04 May 2018

BRIEF-G1 Therapeutics Files For Offering Of 3 Mln Shares

* FILES FOR OFFERING OF 3 MILLION SHARES OF ITS COMMON STOCK Source text: (http://bit.ly/2D2beLO) Further company coverage:

06 Mar 2018

BRIEF-G1 Therapeutics Announces Positive Trilaciclib Phase 2A Topline Data Showing Robust Myelopreservation Benefits In Patients With Small Cell Lung Cancer

* G1 THERAPEUTICS ANNOUNCES POSITIVE TRILACICLIB PHASE 2A TOPLINE DATA SHOWING ROBUST MYELOPRESERVATION BENEFITS IN PATIENTS WITH SMALL CELL LUNG CANCER

05 Mar 2018

BRIEF-G1 Therapeutics Qtrly Net Loss Per Share $0.60

* G1 THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS

22 Feb 2018

Earnings vs. Estimates